Newtopia Reports Fourth Quarter, Full Year 2023 and First Quarter 2024 Financial Results

In This Article:

Newtopia is emboldened by our immediate growth prospects based on three exciting developments in the market:

  1. Growth of GLP-1s opens a huge market for Newtopia to demonstrate sustainability and ROI.

  2. Rise of Health AI and next-gen clinical discovery requires Newtopia's novel data and capabilities.

  3. Expansion opportunities with Heartland Whole Health Institute based on Newtopia's best-ever reported outcomes.

TORONTO, May 23, 2024 /PRNewswire/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, today announced its fourth quarter, fiscal 2023 and first quarter 2024 financial results, operational highlights and filing of its annual financial statements. These results pertain to the three months and year ended December 31, 2023 as well as the three months ended March 31, 2024. All amounts are expressed in Canadian dollars, unless otherwise noted. The foregoing is a summary of selected information for the years ended December 31, 2023 and 2022 in addition to the quarter ending March 31, 2024 and is qualified in its entirety by, and should be read in conjunction with, Newtopia's consolidated financial statements and management discussion and analysis for the respective periods. The Company expects such financial statements to be filed on May 28, 2024 and will be available on SEDAR+ at www.sedarplus.com.

Fourth Quarter 2023 Financial Highlights (vs. Q4 2022):

  • Revenue of $2.3 million, as compared to $3.1 million.

  • Gross profit margin1 of 63%, as compared to 65%.

Full Year 2023 Financial Highlights (vs. 2022):

  • Revenue of $9.8 million, as compared to $11.2 million.

  • Gross profit margin1 of 62%, as compared to 53%.

First Quarter 2024 Financial Highlights (vs. Q1 2023):

  • Revenue of $1.8 million, as compared to $2.6 million.

  • Gross profit margin1 of 50%, as compared to 60%.

"We see three distinct and exciting strategic areas of opportunity for growth for Newtopia including: (1) expanding our key innovation partnerships, such as Heartland Whole Health Institute; (2) combining Newtopia's proven habit change platform with GLP-1 drugs for obesity and type 2 diabetes; and (3) partnering with health AI and clinical discovery innovators to improve our collective ability to deliver best in breed outcomes that prevent, reverse and slow chronic disease, said Jeff Ruby, Founder and CEO of Newtopia.

"Throughout 2023 and in early 2024, we've made great strides in reducing our cost to serve participants while at the same time increasing our operational efficiencies – all while maintaining and improving our industry leading engagement and whole health outcomes. In the first quarter of 2024, we delivered our best ever outcomes for the first two cohorts of our innovative health coaching project with the Heartland Whole Health Institute in Northwest Arkansas," said Jeff Ruby, Founder and CEO of Newtopia.